New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | all day >>
07:38 EDTALXN, GEVAAlexion volatility flat into acquiring Synageva for $230 per share
Subscribe for More Information
07:38 EDTADHDAlcobra reports Q1 EPS (26c), consensus (29c)
Subscribe for More Information
07:38 EDTWENWendy's backs FY15 adjusted EPS 33c-35c, consensus 33c
Backs FY15 adjusted EBITDA $390M-$400M. Remains on target for G&A expense of $250M in 2015. Sees FY15 same restaurant sales growth of 2.5%-3% at company-operated restaurants. Sees FY15 company-operated restaurant margin of 16.5%-17%. The company's 2015 outlook also assumes the ownership of approximately 380 fewer restaurants at year end 2015 compared to 957 Company-operated restaurants at year-end 2014. The Company's expected year-end restaurant count contemplates the anticipated sale of approximately 100 restaurants from its Canadian system optimization initiative, in addition to the planned sale of approximately 280 of the 540 additional domestic restaurants that the Company intends to sell by the middle of 2016.
07:38 EDTAYRAircastle reports Q1 adjusted EPS 62c, consensus 52c
Subscribe for More Information
07:37 EDTCTB, TWI, GTTire & Rubber sector downgraded to Neutral from Attractive at Goldman
Subscribe for More Information
07:37 EDTEXKEndeavour Silver reports Q1 EPS 1c, consensus (5c)
Reports Q1 revenue $51.1M vs. $53M last year. Silver production decreased 4% to 1,820,050 oz; Gold production decreased 15% to 15,808 oz; Silver equivalent production decreased 8% to 2.9 million oz. Silver oz sold up 21% to 1,861,975 oz; Gold oz sold down 4% to 15,799 oz.
07:37 EDTSCORcomScore upgraded on Q1 results,valuation at Oppenheimer
Subscribe for More Information
07:37 EDTZIXIZixCorp's email data protection selected Miller Group
Subscribe for More Information
07:36 EDTWENWendy's on schedule to complete debt refinancing on June 1
As previously announced, the company plans to recapitalize its balance sheet, targeting a leverage ratio of five to six times net debt to 2014 Adjusted EBITDA. The company expects the transaction to close on June 1, 2015, and intends to return the net proceeds to shareholders via a share repurchase program.
07:36 EDTARIAARIAD announces commercial distribution agreement for Iclusig in Turkey
Subscribe for More Information
07:36 EDTNXPINXP Semiconductors management to meet with Deutsche Bank
Subscribe for More Information
07:36 EDTSBGISinclair Broadcast sees FY15 CapEx $90.0M
Sees FY15 barter and trade revenue $106.6M. Sees FY15 barter expense $91.1M. Sees FY15 corporate overhead $57.6M.
07:36 EDTWENWendy's announces acceleration of Image Activation program
Subscribe for More Information
07:36 EDTDNRDenbury Resources sees FY15 production 72,500-75,500 BOE/d
Subscribe for More Information
07:35 EDTDRNADicerna presents preclinical data on DsiRNA-EX technology
Dicerna Pharmaceuticals presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology in enabling direct delivery of its RNAi-based investigational therapy to the liver via subcutaneous injection. In an oral presentation at the 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics from Research through Commercialization Conference in San Diego, Calif., Bob D. Brown, Ph.D., chief scientific officer and senior vice president of research at Dicerna, reported on experiments in non-human primates in which subcutaneous administration of DsiRNA-EX Conjugates resulted in potent and durable knockdown of HAO1, a gene implicated in the pathogenesis of primary hyperoxaluria type 1. An orphan disease, PH1 is a rare, inherited liver disorder that often results in progressive and severe kidney damage. At the TIDES conference, Dr. Brown reported potent, durable knockdown of HAO1, along with prolonged liver exposure, in non-human primates following single and multiple subcutaneous doses. He noted that the results in animal models were obtained with multiple independent sequences, suggesting a potentially reproducible and broadly applicable platform.
07:35 EDTWENWendy's intends to sell total of 380 restaurants in 2015
Subscribe for More Information
07:35 EDTDISDisney price target raised to $121 from $110 at JPMorgan
Subscribe for More Information
07:35 EDTKELYAKelly Services reports Q1 EPS 10c, consensus 12c
Reports Q1 revenue $1.32B, consensus $1.37B.
07:35 EDTTreasury Market Outlook: Treasuries are modestly lower
Subscribe for More Information
07:34 EDTWEXWEX Inc. announces launch of WEX FlexCard
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use